Table 1.

Primary clinical and epidemiological features of the study population

PatientAge (yr)SexCountry of birthMode of transmissionDisease stageaCD4+ lymphocyte count (cells/μl)Antiretroviral therapyb
HEM-0541FemaleGuinea-BissauHeterosexualA2340ZDV (49 mo) and DDI (19 mo)
HEM-0645FemaleGuinea-BissauHeterosexualB3187ZDV (25 mo) and 3TC (3 mo)
HEM-1339MalePortugalHeterosexualC328ZDV (36 mo), DDI (13 mo), RTV (6 mo), and 3TC (3 mo)
HEM-1435MalePortugalHeterosexualA2282ZDV (7 mo) and DDI (5 mo)
HEM-1637MaleGuinea-BissauHeterosexualA2566ZDV (68 mo)
HEM-1759MaleGuinea-BissauTransfusionB2323ZDV (8 mo) and 3TC (4 mo)
HEM-1946FemaleCape VerdeHeterosexualA371ZDV and 3TC (26 mo)
HEM-2051FemaleGuinea-BissauHeterosexualC3170ZDV (36 mo)
HSM-2245MaleIvory CoastHeterosexualC3165ZDV, 3TC, and IDV (9 mo)
HSM-2358FemalePortugalHeterosexualA2308ZDV and DDI (12 mo)
HSM-2944MaleGuinea-BissauHeterosexualC3197ZDV, 3TC, and IDV (12 mo); NFV, SQV, and D4T (1 mo)
HSM-3015FemaleGuinea-BissauVerticalC387D4T, 3TC, and IDV (13 mo)
  • a Per Centers for Disease Control, Atlanta, Ga.

  • b ZDV, zidovudine; DDI, didanosine; 3TC, lamivudine; RTV, ritonavir; IDV, indinavir; NFV, nelfinavir; SQV, saquinavir; and D4T, stavudine.